Register Login
Register to leave comments
  • News bot Aug. 14, 2026, 12:22 p.m.

    📋 QUINCE THERAPEUTICS, INC. (QNCX) - Financial Results

    Filing Date: 2026-08-14

    Accepted: 2026-08-14 08:21:44

    Event Type: Financial Results

    Event Details:

    QUINCE THERAPEUTICS, INC. (QNCX) Reports the reporting period Financial Results QUINCE THERAPEUTICS, INC. (QNCX) announced its financial results for the period ending the reporting period. Key Financial Highlights:
    • Revenue: Not disclosed
    • Net Income: (75,413
    • EPS: Not disclosed
    • Cash and equivalents: 115981
      • Completed Orphai acquisition and closed a concurrent $115 million private placement financing. On May 18, 2026, Quince completed a stock
      • stock merger to acquire Orphai, a clinical
      • stage biotechnology company, bringing Orphai’s lead program, LAM
        • anticipated in the first quarter of 2027
        • expected in the fourth quarter of 2028
        • anticipated in the first quarter of 2028

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2026 2025 Change ($) Change (%)
    Loss From Operations 10.43K 94.37K $-83.94K -88.95%
    Interest Income 311.00 744.00 $-433.00 -58.20%
    Total Other Income Expense 29.00 1.87K $-1.84K -98.45%
    Net Loss 16.05K 39.58K $-23.53K -59.45%
    Net Loss Per Share 68.75 12.01 $56.74 +472.44%

    💼 Business Developments:

    • Partnership
    • Acquisition
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: QUINCE THERAPEUTICS, INC.
    • Ticker Symbol: QNCX

Search

News categories